// App-Quantinova.ai

P132 : Analysis of various central endoscopy reading methodologies in the BERGAMOT exploratory induction cohort evaluating etrolizumab in Crohn’s Disease

Researchers

Presenter

  • W Reinisch

Principal Investigators

  • D S Mishkin

  • Y S Oh

  • S Schreiber

  • R Maciuca

  • R Jacob

  • A Hassanali

  • U Arulmani

  • M Daperno

Medical Centers

  • Medical University of Vienna, Vienna, Austria

  • Atrius Health, Boston, MA

  • Genentech, Inc., South San Francisico, CA

  • Christian-Albrechts-University, Kiel, Germany

  • Roche Products Limited, Welwyn Garden City

  • AO Ordine Mauriziano, TORINO, Italy

Locations

  • Austria

  • United States

  • Germany

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Etrolizumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved